tradmap

WRBY Warby Parker Inc.

$26.11 +22.76%

Data as of close

Healthcare · Ophthalmic Goods

Warby Parker Inc. (WRBY) is a healthcare company in the Ophthalmic Goods industry, with a market capitalization of $3.2 billion. Shares last traded at $26.11, 15.8% below their 52-week high. Over the past year the stock is up 32.9%. WRBY trades at a price-to-earnings ratio of 434.46, above the Ophthalmic Goods median of 231.29. Net profit margin is 0.8%, above the peer median of 0.5%. Revenue grew 13.0% year over year.

Market Cap
$3.2B
Shares Out
124.3M
EPS (TTM)
$0.05
P/E (TTM)*
434.46
P/S Ratio
3.47
P/B Ratio
8.05
Dividend / Share
—
Dividend Yield
—
52-Week High
$31.00
52-Week Low
$14.97
Volume (venue)
574,200
Avg Vol (3m, venue)
199,463.381

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+6.22%
1M
+3.12%
3M
-1.32%
6M
-4.01%
YTD
+19.85%
1Y
+32.91%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
55.34
SMA (50)
$24.90
SMA (200)
$25.08
Price vs SMA50
+4.86%
Price vs SMA200
+4.11%
ATR (14)
$1.93

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$935M
Net Income
$7M
Gross Margin
54.7%
Operating Margin
0.2%
Net Margin
0.8%
Return on Equity
1.9%
Return on Assets
0.9%
Current Ratio
2.26
Debt / Equity
0.96
Revenue Growth (YoY)
+13.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.04 2026-11-05
Q2 2026 $0.04 2026-08-06
Q1 2026 $0.03 2026-05-07
Q4 2025 (derived) -$0.06 2026-02-26
FY 2025 $0.01 2026-02-26
Q3 2025 $0.05 2025-11-06

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Ophthalmic Goods peers

WRBY vs 8 industry peers (Ophthalmic Goods), by market cap. Data as of close

P/E vs peers
434.46 / 231.29 med
+88% premium
P/S vs peers
3.47 / 2.25 med
+55% premium
Net margin vs peers
0.8% / 0.5% med
above median
1–8 of 8
ALCAlcon Inc$37.3B———-1.02%
COOCooper Companies (The)$12.1B21.172.8513.5%-1.44%
BLCOBausch & Lomb Corp$7.1B—1.32-2.0%-3.30%
WRBYWarby Parker Inc.$3.2B434.463.470.8%+22.76%
EYENational Vision Holdings, Inc.$1.4B28.110.702.5%-0.28%
STAAStaar Surgical Co$1.3B2529.984.080.2%-1.51%
RXSTRxsight, Inc.$190M—1.64-46.3%-9.24%
LUCYInnovative Eyewear Inc$7M———+0.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.